Alpha 2.0
Login Register
» Authors » James Tibenderana

James Tibenderana

Explore the profile of James Tibenderana including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 26
Citations 504
Followers 0
Related Specialties
Tropical Medicine
General Medicine
Public Health
Top 10 Co-Authors
Karin Kallander
Jimmy Opigo
Prudence Hamade
Betty Kirkwood
Zelee Hill
Sylvia Meek
Jane Achan
Helen Counihan
Anthony Nuwa
Godfrey Magumba
Published In
Malar J
PLoS One
Lancet
Glob Health Sci Pract
Glob Health Action
Affiliations
Soon will be listed here.
Recent Articles
1.
Effectiveness of sulfadoxine-pyrimethamine plus amodiaquine and dihydroartemisinin-piperaquine for seasonal malaria chemoprevention in Uganda: a three-arm, open-label, non-inferiority and superiority, cluster-randomised, controlled trial
Nuwa A, Baker K, Kajubi R, Nnaji C, Theiss-Nyland K, Odongo M, et al.
Lancet Infect Dis . 2025 Jan; PMID: 39826559
Background: Seasonal malaria chemoprevention (SMC) with sulfadoxine-pyrimethamine combined with amodiaquine (SPAQ) effectively protects eligible children from malaria in areas of high and seasonal transmission. However, concerns about parasite resistance to...
2.
Regional action needed to halt antimalarial drug resistance in Africa
Martinez-Vega R, Ishengoma D, Gosling R, Rosenthal P, Dondorp A, Barnes K, et al.
Lancet . 2024 Dec; 405(10472):7-10. PMID: 39674185
No abstract available.
3.
A hybrid effectiveness-implementation study protocol to assess the effectiveness and chemoprevention efficacy of implementing seasonal malaria chemoprevention in five districts in Karamoja region, Uganda
Kajubi R, Ainsworth J, Baker K, Richardson S, Bonnington C, Rassi C, et al.
Gates Open Res . 2024 Jan; 7:14. PMID: 38196920
Background: The World Health Organization (WHO) recommends seasonal malaria chemoprevention (SMC) with sulfadoxine-pyrimethamine and amodiaquine (SPAQ) for children aged 3 to 59 months, living in areas where malaria transmission is...
4.
Improving outcomes for children with malaria, diarrhoea and pneumonia in Mozambique: A cluster randomised controlled trial of the inSCALE technology innovation
Soremekun S, Kallander K, Lingam R, Branco A, Batura N, Strachan D, et al.
PLOS Digit Health . 2023 Jun; 2(6):e0000235. PMID: 37307522
Background: The majority of post-neonatal deaths in children under 5 are due to malaria, diarrhoea and pneumonia (MDP). The WHO recommends integrated community case management (iCCM) of these conditions using...
5.
Improving community health worker treatment for malaria, diarrhoea, and pneumonia in Uganda through inSCALE community and mHealth innovations: A cluster randomised controlled trial
Kallander K, Soremekun S, Strachan D, Hill Z, Kasteng F, Kertho E, et al.
PLOS Digit Health . 2023 Jun; 2(6):e0000217. PMID: 37307519
The inSCALE cluster randomised controlled trial in Uganda evaluated two interventions, mHealth and Village Health Clubs (VHCs) which aimed to improve Community Health Worker (CHW) treatment for malaria, diarrhoea, and...
6.
Developing African arbovirus networks and capacity strengthening in arbovirus surveillance and response: findings from a virtual workshop
Braack L, Wulandhari S, Chanda E, Fouque F, Merle C, Nwangwu U, et al.
Parasit Vectors . 2023 Apr; 16(1):129. PMID: 37059998
This meeting report presents the key findings and discussion points of a 3-h virtual workshop, held on 21 September 2022, and organized by the "Resilience Against Future Threats through Vector...
7.
A non-randomized controlled trial to assess the protective effect of SMC in the context of high parasite resistance in Uganda
Nuwa A, Baker K, Bonnington C, Odongo M, Kyagulanyi T, Bwanika J, et al.
Malar J . 2023 Feb; 22(1):63. PMID: 36814301
Background: Until recently, due to widespread prevalence of molecular markers associated with sulfadoxine-pyrimethamine (SP) and amodiaquine (AQ) resistance in east and southern Africa, seasonal malaria chemoprevention (SMC) has not been...
8.
District-led malaria surveillance and response as an effective way to manage malaria upsurges following the withdrawal of indoor residual spraying: a case study from Nwoya District, northern Uganda
Nuwa A, Oola J, Obonyo S, Feldman M, Karungi S, Kertho E, et al.
Malar J . 2022 Feb; 21(1):55. PMID: 35183190
Background: Malaria remains the number one cause of morbidity and mortality in Uganda. In 2009, the United States President's Malaria Initiative (PMI) funded an indoor residual spraying (IRS) project in...
9.
Correction to: Efficacy and safety of artemether-lumefantrine and dihydroartemisinin-piperaquine for the treatment of uncomplicated Plasmodium falciparum malaria and prevalence of molecular markers associated with artemisinin and partner drug...
Ebong C, Sserwanga A, Namuganga J, Kapisi J, Mpimbaza A, Gonahasa S, et al.
Malar J . 2022 Feb; 21(1):37. PMID: 35130919
No abstract available.
10.
A practical approach for geographic prioritization and targeting of insecticide-treated net distribution campaigns during public health emergencies and in resource-limited settings
Young A, Eaton W, Worges M, Hiruy H, Maxwell K, Audu B, et al.
Malar J . 2022 Jan; 21(1):10. PMID: 34983558
Background: The use of data in targeting malaria control efforts is essential for optimal use of resources. This work provides a practical mechanism for prioritizing geographic areas for insecticide-treated net...